Lead Product(s): Inzomelid
Therapeutic Area: Neurology Product Name: IZD174
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $441.9 million
Deal Type: Acquisition September 21, 2020
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.